ACADIA Pharmaceuticals Inc.

LSE:0A4W Stock Report

Market Cap: US$2.8b

ACADIA Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

ACADIA Pharmaceuticals has been growing earnings at an average annual rate of 31.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 18.9% per year. ACADIA Pharmaceuticals's return on equity is 22.3%, and it has net margins of 13.8%.

Key information

31.9%

Earnings growth rate

33.5%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate18.9%
Return on equity22.3%
Net Margin13.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ACADIA Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

LSE:0A4W Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 249291294700
30 Jun 24891314340
31 Mar 24814-24130
31 Dec 23726-614070
30 Sep 23632-1493990
30 Jun 23551-1113800
31 Mar 23520-1463740
31 Dec 22517-2163690
30 Sep 22512-2173710
30 Jun 22512-2053740
31 Mar 22493-2143810
31 Dec 21484-1683960
30 Sep 21474-1924110
30 Jun 21463-2624110
31 Mar 21458-2603980
31 Dec 20442-2823890
30 Sep 20419-2683600
30 Jun 20393-2253510
31 Mar 20366-2383350
31 Dec 19339-2353260
30 Sep 19300-2483080
30 Jun 19264-2682960
31 Mar 19238-2762980
31 Dec 18224-2452660
30 Sep 18208-2492580
30 Jun 18185-2522590
31 Mar 18158-2562500
31 Dec 17125-2892550
30 Sep 1793-2992460
30 Jun 1763-3062350
31 Mar 1733-3092250
31 Dec 1617-2711860
30 Sep 165-2381510
30 Jun 160-2061210
31 Mar 160-174920
31 Dec 150-164790
30 Sep 150-147670
30 Jun 150-133540
31 Mar 150-115410
31 Dec 140-92330
30 Sep 140-76270
30 Jun 140-62220
31 Mar 141-50170
31 Dec 131-38130

Quality Earnings: 0A4W has high quality earnings.

Growing Profit Margin: 0A4W became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 0A4W has become profitable over the past 5 years, growing earnings by 31.9% per year.

Accelerating Growth: 0A4W has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 0A4W has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).

Return on Equity

High ROE: 0A4W's Return on Equity (22.3%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 02:30
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ACADIA Pharmaceuticals Inc. is covered by 37 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert LeBoyerAegis Capital Corporation
Joel BeattyBaird
Ishan MajumdarBaptista Research